Outcomes of Lung Transplantation From Hepatitis C Viremic Donors

BACKGROUND Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has encouraged lung transplantation with HCV positive donors. Early trials have been promising; however, nationwide data have not been previously examined. METHODS The United Network for Organ Sharing registry was queried for adult patients receiving lung transplants from 2016 to 2019. We excluded multiorgan transplants, incomplete data, and loss to follow-up. Nucleic acid testing (NAT) determined HCV status. Propensity matching was performed for comparison of outcomes. RESULTS Hepatitis C virus NAT-positive lungs were transplanted in 189 patients, compared with 9511 recipients of NAT-negative lungs. The HCV NAT-positive donors were younger (mean 33 vs 35 years, P =.017) with higher rates of PaO2/FiO(2) greater than 300 (83.6% vs 76.5%, P =.029). Recipients of NAT-positive lungs had lower lung allocation scores (mean 39.3 vs 42.4, P =.009). Distance traveled was significantly further for HCV viremic donor lungs (mean 416 vs 206 miles, P <.001). Kaplan-Meier survival analysis demonstrated no difference in survival (P =.56). There were no differences in airway dehiscence (P =.629), acute rejection (P >.999), or reintubation (P =.304). At mean follow-up of 395 days, 63 recipients of NAT-positive lungs (40%) seroconverted, 14 with viremia. One-year mortality rates among seroconverted patients was 6% and did not differ significantly from 14% in nonseroconverted patients or 13.2% in recipients of HCV-negative lungs. CONCLUSIONS Short-term outcomes of lung transplantation from HCV viremic donors are promising, with no difference in early complications or survival. The effects of seroconversion and long-term outcomes including chronic rejection and infection need to be further explored. (C)2022 by The Society of Thoracic Surgeons